Nov 21, 2025 12:07PM
Sep 19, 2025 05:00PM
Sep 19, 2025 05:00PM
Sep 5, 2025 07:51PM
Sep 5, 2025 07:50PM
Aug 11, 2025 07:28PM
Aug 11, 2025 07:28PM Revive Therapeutics Announces Closing of First Tranche of Private Placement and Debt Settlement
Jul 30, 2025 08:21PM
Jul 8, 2025 05:10PM
Jun 4, 2025 06:55AM
May 12, 2025 02:07PM
Apr 10, 2025 07:00AM
Mar 19, 2025 09:14AM
Feb 3, 2025 05:00PM Revive Therapeutics Announces Update on R&D Focus on Bucillamine for Infectious Diseases and Medical Countermeasures
Jul 2, 2024 01:58PM
Jun 12, 2024 09:05AM
Mar 27, 2024 09:08AM
Feb 26, 2024 04:05PM
Jan 31, 2024 05:06PM
Jan 24, 2024 05:55PM
Dec 20, 2023 12:54PM Revive Therapeutics Announces Results of Annual General and Special Meeting of Shareholders
Oct 11, 2023 08:50AM
May 2, 2023 06:00AM
Apr 18, 2023 06:44PM
Apr 3, 2023 07:00AM
Mar 28, 2023 07:00AM
Mar 20, 2023 08:28AM
Mar 8, 2023 07:45AM Revive Therapeutics Provides Update From Type C Meeting with FDA for Amended Protocol Agreement of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19
Feb 6, 2023 08:00AM
Feb 6, 2023 08:00AM
Feb 3, 2023 06:00AM
Jan 19, 2023 04:50PM
Jan 12, 2023 01:14PM
Jan 12, 2023 06:00AM
Jan 9, 2023 03:34PM Revive Therapeutics Announces Publication Showing Bucillamine’s Potential Impact on COVID-19 Omicron Variants
Jan 5, 2023 09:19AM
Dec 22, 2022 02:00PM
Dec 15, 2022 07:29AM
Nov 30, 2022 05:43PM
Nov 24, 2022 09:18AM
Nov 22, 2022 09:20AM
Oct 14, 2022 01:34PM Revive Therapeutics Announces Finalization of Amended Phase 3 COVID-19 Study Protocol to FDA
Oct 6, 2022 10:18AM
Sep 28, 2022 07:00AM
Sep 16, 2022 06:00AM
Sep 14, 2022 06:00AM
Aug 16, 2022 06:00AM
Jul 25, 2022 10:57AM
Jun 24, 2022 11:41AM Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19
Jun 6, 2022 01:54PM

312,667 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All